製品名:5-fluoro-4-iodo-2-methylaniline

IUPAC Name:5-fluoro-4-iodo-2-methylaniline

CAS番号:307306-08-7
分子式:C7H7FIN
純度:95%+
カタログ番号:CM192660
分子量:251.04

包装単位 有効在庫 価格(USD) 数量
CM192660-1g in stock ǯƄ
CM192660-5g in stock ưźĽ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:307306-08-7
分子式:C7H7FIN
融点:-
SMILESコード:NC1=CC(F)=C(I)C=C1C
密度:
カタログ番号:CM192660
分子量:251.04
沸点:
MDL番号:MFCD21364952
保管方法:Store at 2-8°C.

Category Infos

New
Custom Organic Synthesis,Where to Buy Chemical Building Blocks - Chemenu
Pharmaceutical intermediates, bulk products, chiral, achiral, heterocycles, metal catalysts, amino acids, peptides, benzene, pyridine, pyrazine, triazine, piperidine, piperazine, morpholine, imidazoline, cyclopropane, indole, benzotriazole, anthranil, quinoline, naphthalene, boronic compounds, fluorination, oxidation, rearrangement reaction
Chemenu product lines cover amino acids and peptides, heterocyclic compounds, alkanes and aromatic compounds, carbohydrates, alcohols, aldehydes & ketones, pyridazines, metal catalysts and other pharmaceutical intermediates. For more custom organic synthesis, please contact us for a quote.

Column Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Vebreltinib
Avistone announced that they received conditional approval from the National Medical Products Administration (NMPA) to commercialize Vebreltinib (Bozitinib) to treat patients with MET exon 14 skipping non-small cell lung cancer (NSCLC) in China. The conditional approval was based on results from a pivotal Phase II KUNPENG study with an objective response rate (ORR) of 75.0% and median progression-free survival (PFS) in patients with advanced METex14 mutations to 14.1 months with a good safety profile as was recently presented at the 2023 European Society for Clinical Oncology (ESMO) Congress in Madrid, Spain. Vebreltinib is a potent, small molecule, orally bioavailable and highly selective c-Met Tyrosine Kinase Inhibitor (TKI).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products